UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000034723
Receipt number R000039578
Scientific Title General Drug Use Survey of HERNICORE 1.25 units for intradiscal injection in Patients with Lumbar Disc Herniation
Date of disclosure of the study information 2018/11/01
Last modified on 2023/10/13 13:16:07

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

General Drug Use Survey of HERNICORE 1.25 units for intradiscal injection in Patients with Lumbar Disc Herniation

Acronym

HERNICORE General Drug Use Survey

Scientific Title

General Drug Use Survey of HERNICORE 1.25 units for intradiscal injection in Patients with Lumbar Disc Herniation

Scientific Title:Acronym

HERNICORE General Drug Use Survey

Region

Japan


Condition

Condition

Lumbar Disc Herniation

Classification by specialty

Orthopedics Neurosurgery

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To detect safety (detection of unknown adverse drug reactions and understanding of the occurrence of other adverse drug reactions) and efficacy under actual conditions of use as well as factors affecting them

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Safety
- Occurrence of adverse events and adverse reactions
- Occurrence of post-treatment surgery for lumbar spinal instability at the same level of administration of HERNICORE
Efficacy
- Improvement of leg pain and low back pain
- Occurrence of post-treatment surgery for lumbar disc herniation at the same level of administration of HERNICORE - Global assessment (physician)

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

HERNICORE naive patients with subligamentous extruded lumbar disc herniation with no sufficient improvement after a conservative therapy

Key exclusion criteria

None

Target sample size

3000


Research contact person

Name of lead principal investigator

1st name Tadamasa
Middle name
Last name Kobayashi

Organization

SEIKAGAKU CORPORATION

Division name

Pharmacovigilance Dept.

Zip code

100-0005

Address

6-1, Marunouchi 1-chome, Chiyoda-ku, Tokyo

TEL

03-5220-8556

Email

HER_GPSP_2_SKK@seikagaku.co.jp


Public contact

Name of contact person

1st name Kazuki
Middle name
Last name Endo

Organization

SEIKAGAKU CORPORATION

Division name

Pharmacovigilance Dept.

Zip code

100-0005

Address

6-1, Marunouchi 1-chome, Chiyoda-ku, Tokyo

TEL

03-5220-8556

Homepage URL


Email

HER_GPSP_2_SKK@seikagaku.co.jp


Sponsor or person

Institute

SEIKAGAKU CORPORATION

Institute

Department

Personal name



Funding Source

Organization

SEIKAGAKU CORPORATION

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

SEIKAGAKU CORPORATION

Address

6-1, Marunouchi 1-chome, Chiyoda-ku, Tokyo

Tel

03-5220-8556

Email

HER_GPSP_2_SKK@seikagaku.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 11 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2018 Year 09 Month 07 Day

Date of IRB

2018 Year 09 Month 07 Day

Anticipated trial start date

2018 Year 12 Month 03 Day

Last follow-up date

2022 Year 09 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded

2026 Year 05 Month 31 Day


Other

Other related information

Planned registration period: November 2018 - December 2021
Registration method: Central registration method
Observation period: 3 months after administration

Ethics Committee approval not applicable for investigation.


Management information

Registered date

2018 Year 10 Month 31 Day

Last modified on

2023 Year 10 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039578


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name